A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study-Reference-Cited by-同舟云学术

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Published:2013-05-16 Issue:10 Volume:72 Page:1605-1612
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Park Won,Hrycaj Pawel,Jeka Slawomir,Kovalenko Volodymyr,Lysenko Grygorii,Miranda Pedro,Mikazane Helena,Gutierrez-Ureña Sergio,Lim MieJin,Lee Yeon-Ah,Lee Sang Joon,Kim HoUng,Yoo Dae Hyun,Braun Jürgen

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference32 articles.

1. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial;Braun;Lancet,2002

2. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT);van der Heijde;Arthritis Rheum,2005

3. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study;Braun;Arthritis Rheum,2006

4. Sustained reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab;Braun;Ann Rheum Dis,2007

5. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis;Braun;Ann Rheum Dis,2011

Cited by 528 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease;Arab Journal of Gastroenterology;2024-08

3. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

4. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

5. Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan;Expert Opinion on Biological Therapy;2024-07-02